Where can I buy BCEL shares?
Shares of BCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
How much did BCEL raise in its IPO?
(BCEL) raised $126 million in an initial public offering on Thursday, June 20th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel served as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.
Will BCEL outperform or underperform the S&P 500?
MarketBeat's community ratings are surveys of what our community members think about Atreca and other stocks. Vote “Outperform” if you believe BCEL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BCEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
Is Bcel stock a good buy?
Atreca Inc (NASDAQ:BCEL) The 9 analysts offering 12-month price forecasts for Atreca Inc have a median target of 14.00, with a high estimate of 25.00 and a low estimate of 4.00. The median estimate represents a +573.08% increase from the last price of 2.08.
Why did Bcel stock drop?
Summary. BCEL has very high smart money involvement. Poor adverse event data brought the stock down in July. The pipeline is in very early stage.
Should I buy or sell Atreca stock right now?
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last year. There are currently 5 buy ratings for th...
What is Atreca's stock price forecast for 2022?
5 Wall Street research analysts have issued 1 year price objectives for Atreca's shares. Their forecasts range from $9.00 to $30.00. On average, th...
How has Atreca's stock performed in 2022?
Atreca's stock was trading at $3.03 on January 1st, 2022. Since then, BCEL shares have decreased by 35.3% and is now trading at $1.96. View the be...
When is Atreca's next earnings date?
Atreca is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for Atreca .
How were Atreca's earnings last quarter?
Atreca, Inc. (NASDAQ:BCEL) issued its quarterly earnings data on Wednesday, May, 11th. The company reported ($0.65) earnings per share for the quar...
Who are Atreca's key executives?
Atreca's management team includes the following people: Mr. John A. Orwin , Pres, CEO & Director (Age 57, Pay $863.52k) Mr. Herbert C. Cross ,...
What is John Orwin's approval rating as Atreca's CEO?
2 employees have rated Atreca CEO John Orwin on Glassdoor.com . John Orwin has an approval rating of 100% among Atreca's employees. This puts John...
Who are some of Atreca's key competitors?
Some companies that are related to Atreca include Pardes Biosciences (PRDS) , Edgewise Therapeutics (EWTX) , Aadi Bioscience (AADI) , AC Immune...
What other stocks do shareholders of Atreca own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Atreca investors own include Alector (ALEC) , Editas Medi...
About Atreca
Atreca (NASDAQ:BCEL) Frequently Asked Questions
Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response.
Recently Viewed Tickers
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Atreca stock. View analyst ratings for Atreca or view top-rated stocks.
Atreca Inc. Cl A
Visit a quote page and your recently viewed tickers will be displayed here.
Atreca, Inc. - (BCEL) Company Bio
Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response.
Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case
Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response.
Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as Drugs
Investment Thesis One of the reasons given for the biotech industry's surprising fall from grace in 2021 - its flagship XBI index is down by 45% over the past 12 months - is the record-breaking number of IPOs completed last year and the year before. According to Biopharmadive there were...
Goldman Sachs Group Inc. Lowers Stock Holdings in Atreca, Inc. (NASDAQ:BCEL)
SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc.
Atreca Inc. (BCEL): What Is Good About Stock?
Goldman Sachs Group Inc. cut its stake in shares of Atreca, Inc. (NASDAQ:BCEL) by 63.0% in the 2nd quarter, Holdings Channel reports. The fund owned 99,913 shares of the companys stock after selling 170,340 shares during the quarter. Goldman Sachs Group Inc.s holdings in Atreca were worth $851,000 as of its most recent filing with []
State Street Corp Sells 634,868 Shares of Atreca, Inc. (NASDAQ:BCEL)
Atreca Inc. (NASDAQ:BCEL) has seen 1.87 million shares traded in the last trading session. The company, currently valued at $134.16M, closed the last trade at $3.59 per share which meant it lost -$0.36 on the day or -9.11% during that session. The BCEL stock price is -465.18% off its 52-week high price of $20.29 and Atreca Inc.
